Finance
Finance
⎀⎙⎅⎙āļŗāļ´āˇœāˇ…⎀āļŊ⎊
AstraZeneca plc
GBX 11,072.00
āļ…āļœāˇ 12, 17.33.48 āļœāˇŠâ€āļģ⎒āļ¸āˇ€āˇš+1 · GBX · LON · ⎀⎒āļēāˇāļ āļąāļē
āļ­āˇœāļœGB āˇƒāˇ”āļģ⎐āļšāˇ”āļ¸ āļŊ⎐āļēāˇ’āˇƒāˇŠāļ­āˇ”āļœāļ­ āļšāļģ āļ‡āļ­GB āļ¸āˇ–āļŊ⎃⎊āļŽāˇāļąāļē āˇ€āˇš
āļ´āˇ™āļģ āˇ€āˇāˇƒāˇ“āļ¸
GBX 11,036.00
āļ¯āˇ’āļą āļ´āļģāˇāˇƒāļē
GBX 10,994.00 - GBX 11,102.00
āˇ€āˇƒāļģ āļ´āļģāˇāˇƒāļē
GBX 9,573.50 - GBX 13,388.00
⎀⎙⎅āļŗāļ´āˇœāˇ… āļ´āˇŠâ€āļģāˇāļœāˇŠāļ°āļąāļē
āļļ⎒234.12 USD
āˇƒāˇāļ¸āˇāļąāˇŠâ€āļēāļē āļ´āļģ⎒āļ¸āˇāˇ€
āļ¸āˇ’2.46
P/E āļ…āļąāˇ”āļ´āˇāļ­āļē
27.99
āļ´āˇŠâ€āļģāļ­āˇ’āļŊāˇāļˇāļē⎚ āļŊāˇāļˇāˇāļ‚⎁āļē
2.21%
āļ¸āˇ–āļŊ⎒āļš āˇ„āˇ”āˇ€āļ¸āˇāļģ⎔⎀
LON
āļ´āˇ”⎀āļ­āˇŠ āļ­āˇ”⎅
āļ¸āˇ–āļŊāˇŠâ€āļē
āļ†āļ¯āˇāļēāļ¸āˇŠ āļ´āˇŠâ€āļģāļšāˇāˇāļē
āļ†āļ¯āˇāļēāļ¸
⎁⎔āļ¯āˇŠāļ° āļ†āļ¯āˇāļēāļ¸
(USD)2025 āļĸ⎖āļąāˇ’⎀/⎀ ⎀⎙āļąāˇƒ
āļ†āļ¯āˇāļēāļ¸
āļļ⎒14.4611.74%
āļ¸āˇ™āˇ„⎙āļē⎔āļ¸āˇŠ ⎀⎒āļēāļ¯āļ¸
āļļ⎒8.425.12%
⎁⎔āļ¯āˇŠāļ° āļ†āļ¯āˇāļēāļ¸
āļļ⎒2.4527.14%
⎁⎔āļ¯āˇŠāļ° āļŊāˇāļˇ āļ†āļąāˇŠāļ­āˇ’āļšāļē
16.9513.83%
āļšāˇœāļ§āˇƒāļšāļ§ āļ‰āļ´āˇāļē⎓āļ¸āˇŠ
2.17119.19%
EBITDA
āļļ⎒4.8821.14%
āļļāļŊāˇāļ­āˇŠāļ¸āļš āļļāļ¯āˇ” āļ…āļąāˇ”āļ´āˇāļ­āļē
21.71%—
āļ¸āˇ”⎅⎔ ⎀āļ­āˇŠāļšāļ¸āˇŠ
āļ¸āˇ”⎅⎔ ⎀āļœāļšāˇ“āļ¸āˇŠ
(USD)2025 āļĸ⎖āļąāˇ’⎀/⎀ ⎀⎙āļąāˇƒ
āļ¸āˇ”āļ¯āļŊ⎊ āˇƒāˇ„ āļšāˇ™āļ§āˇ’ āļšāˇāļŊ⎓āļą āļ†āļēāˇāļĸāļą
āļļ⎒7.110.45%
āļ¸āˇ”⎅⎔ ⎀āļ­āˇŠāļšāļ¸āˇŠ
āļļ⎒112.427.75%
āļ¸āˇ”⎅⎔ ⎀āļœāļšāˇ“āļ¸āˇŠ
āļļ⎒67.614.43%
āļ¸āˇ”⎅⎔ ⎃āļ¸āļšāˇœāļ§āˇƒāˇŠ
āļļ⎒44.81—
⎄⎒āļŸ āļšāˇœāļ§āˇƒāˇŠ
āļļ⎒1.55—
⎀⎙āļąāˇŠ āļšāļģāˇ€āˇ āļœāˇāļąāˇ“āļ¸āļ§ āļ¸āˇ’āļŊ
3.83—
⎀āļ­āˇŠāļšāļ¸āˇŠāˇ€āļŊ āļ´āˇŠâ€āļģāļ­āˇ’āļŊāˇāļˇ
7.97%—
āļ´āˇŠâ€āļģāˇāļœāˇŠāļ°āļąāļē āļ¸āļ­ āļ´āˇŠâ€āļģāļ­āˇ’āļŊāˇāļˇ
11.58%—
āļ¸āˇ”āļ¯āļŊāˇŠāˇ€āļŊ ⎁⎔āļ¯āˇŠāļ° āˇ€āˇ™āļąāˇƒ
(USD)2025 āļĸ⎖āļąāˇ’⎀/⎀ ⎀⎙āļąāˇƒ
⎁⎔āļ¯āˇŠāļ° āļ†āļ¯āˇāļēāļ¸
āļļ⎒2.4527.14%
āļ¸āˇ™āˇ„⎙āļē⎔āļ¸āˇŠāˇ€āļŊ⎒āļąāˇŠ āļ¸āˇ”āļ¯āļŊ⎊
āļļ⎒3.399.76%
āļ†āļēāˇāļĸāļąāļē⎙āļąāˇŠ āļ¸āˇ”āļ¯āļŊ⎊
-āļļ⎒2.1126.60%
āļ¸āˇ–āļŊāˇŠâ€āļēāļšāļģāļĢāļē⎙āļąāˇŠ āļ¸āˇ”āļ¯āļŊ⎊
āļ¸āˇ’518.00142.39%
āļ¸āˇ”āļ¯āļŊāˇŠāˇ€āļŊ ⎁⎔āļ¯āˇŠāļ° āˇ€āˇ™āļąāˇƒ
āļļ⎒1.82279.80%
āļąāˇ’āļ¯āˇ„āˇƒāˇŠ āļ¸āˇ”āļ¯āļŊ⎊ āļ´āˇŠâ€āļģāˇ€āˇāˇ„āļē
āļļ⎒1.61-19.07%
āļ´āˇ’⎅⎒āļļāļŗ
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation. The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US. AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in SÃļdertälje. Throughout the twentieth century, it grew into the largest pharmaceutical company in Sweden. Wikipedia
āļ¸āˇ–āļŊ⎃⎊āļŽāˇāļąāļē
1999 āļ…āļ´āˇŠâ€āļģ⎚āļŊ⎊ 6
⎀⎙āļļ⎊ āļ…āļŠāˇ€āˇ’āļē
āˇƒāˇšāˇ€āļšāļē⎒āļąāˇŠ
94,300
āļ­āˇ€ ⎃⎜āļēāˇ āļœāļąāˇŠāļą
āļ”āļļ āļ‹āļąāļąāˇŠāļ¯āˇ”⎀āļšāˇŠ āļ¯āˇāļšāˇŠāˇ€āˇ’āļē ⎄⎐āļšāˇ’āļē⎒
āļ¸āˇ™āļ¸ āļŊ⎐āļēāˇ’āˇƒāˇŠāļ­āˇ”⎀ āļ¸āˇ‘āļ­ āˇƒāˇ™āˇ€āˇ“āļ¸āˇŠ, āļ…āļąāˇ”āļœāļ¸āļąāļē āļšāˇ… āˇƒāˇ”āļģ⎐āļšāˇ”āļ¸āˇŠāļ´āļ­āˇŠ āˇƒāˇ„ ⎀⎙āļąāļ­āˇŠ āļšāˇŠâ€āļģ⎒āļēāˇāļšāˇāļģāļšāļ¸āˇŠāˇ€āļŊ⎒āļąāˇŠ āļ‹āļ­āˇŠāļ´āˇāļ¯āļąāļē āļšāļģ āļ‡āļ­. āļ­āˇ€ āļ¯āˇāļą āļœāļąāˇŠāļą

āˇƒāˇ’āļēāļŊ⎔ āļ¸ āļ¯āļ­āˇŠāļ­ āˇƒāˇ„ āļ­āˇœāļģāļ­āˇ”āļģ⎔ “āļ´āˇ€āļ­āˇ’āļą āļ†āļšāˇāļģāļēāļ§â€ ⎃āļ´āļēāˇ āļ‡āļ­āˇŠāļ­āˇš āļ´āˇ”āļ¯āˇŠāļœāļŊ⎒āļš āļ­āˇœāļģāļ­āˇ”āļģ⎔ āļ…āļģāļ¸āˇ”āļĢ⎔ ⎃āļŗāˇ„āˇ āļ´āļ¸āļĢāļšāˇŠ ⎀āļą āļ…āļ­āļģ, āļ‘āļē āļ¸āˇ–āļŊāˇŠâ€āļē āļ‹āļ´āļ¯āˇ™āˇƒāˇŠ āˇ„āˇ ⎀⎙⎅āļŗ āļ…āļģāļ¸āˇ”āļĢ⎔ āˇ„āˇ āļ†āļēāˇāļĸāļą, āļļāļ¯āˇ”, āļąāˇ›āļ­āˇ’āļš, āļœāˇ’āļĢ⎔āļ¸āˇŠāļšāļģāļĢ āˇ„āˇ ⎀⎙āļąāļ­āˇŠ āļ‹āļ´āļ¯āˇ™āˇƒāˇŠ ⎃āļŗāˇ„āˇ āļ…āļ¯āˇ„āˇƒāˇŠ āļąāˇœāˇ€āˇš. Google āļ†āļēāˇāļĸāļą āļ‹āļ´āļ¯āˇšāˇāļšāļē⎙āļšāˇ” āˇ„āˇ āļ¸āˇ–āļŊāˇŠâ€āļē āļ‹āļ´āļ¯āˇšāˇāļšāļē⎙āļšāˇ” āļąāˇœāˇ€āļą āļ…āļ­āļģ āļ¸āˇ™āļ¸ āļŊ⎐āļēāˇ’āˇƒāˇŠāļ­āˇ”⎀āļ§ āļ‡āļ­āˇ”⎅āļ­āˇŠ āļšāļģ āļ‡āļ­āˇ’ āļšāˇ’āˇƒāˇ’āļ¯āˇ” ⎃āļ¸āˇāļœāļ¸āļšāˇŠ āˇ„āˇ āļ‘āļ¸ āˇƒāļ¸āˇāļœāļ¸āˇŠ āˇ€āˇ’āˇƒāˇ’āļąāˇŠ āļąāˇ’āļšāˇ”āļ­āˇŠ āļšāļģāļą āļŊāļ¯ āˇƒāˇ”āļģ⎐āļšāˇ”āļ¸āˇŠāļ´āļ­āˇŠ ⎃āļ¸āˇŠāļļāļąāˇŠāļ°āļē⎙āļąāˇŠ āļšāˇ’āˇƒāˇ’āļ¯āˇ” āļ…āļ¯āˇ„āˇƒāļšāˇŠ, āļąāˇ’āļģ⎊āļ¯āˇšāˇāļēāļšāˇŠ āˇ„āˇ āļ¸āļ­āļēāļšāˇŠ āļ´āˇŠâ€āļģāļšāˇāˇ āļąāˇœāļšāļģāļē⎒. āļšāˇ’āˇƒāˇ’āļēāļ¸āˇŠ ⎀⎙⎅āļŗāˇāļ¸āļšāˇŠ āˇƒāˇ’āļ¯āˇ” āļšāˇ’āļģ⎓āļ¸āļ§ āļ´āˇ™āļģ āļ¸āˇ’āļŊ āļœāļĢāļąāˇŠ ⎃āļ­āˇŠâ€āļēāˇāļ´āļąāļē āļšāˇ’āļģ⎓āļ¸ āˇƒāļŗāˇ„āˇ āļ”āļļ⎚ āļ­āˇāļģāˇāˇ€āˇŠāļšāļģ⎔ āˇ„āˇ āļ¸āˇ–āļŊāˇŠâ€āļē āļąāˇ’āļēāˇāļĸ⎒āļ­āļēāˇāļœāˇ™āļąāˇŠ ⎀⎒āļ¸āˇƒāļąāˇŠāļą. āļ­āˇ€ āļ¯āˇāļą āļœāļąāˇŠāļą
āļ´āˇ”āļ¯āˇŠāļœāļŊāļē⎒āļąāˇŠ āļ¸āˇšāˇ€āˇāļ­āˇŠ ⎃⎜āļēāļ­āˇ’
āˇƒāˇ™āˇ€āˇ“āļ¸
āˇƒāˇ™āˇ€āˇ“āļ¸ āˇ„āˇ’āˇƒāˇŠ āļšāļģāļąāˇŠāļą
āˇƒāˇ™āˇ€āˇ“āļ¸ āˇ€āˇƒāļąāˇŠāļą
Google āļē⎙āļ¯āˇ”āļ¸āˇŠ
āļ´āˇŠâ€āļģāļ°āˇāļą āļ¸āˇ™āļąāˇ”⎀